An updated position statement on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer provides the latest evidence-based guidance, with an ...
Eleven trials with 754 participants, assessing alendronate, clodronate, neridronate, pamidronate, and zoledronate, were included. HealthDay News — Bisphosphonates may reduce complex regional pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results